Get all your news in one place.

100's of premium titles.
One app.

Start reading

Get all your news in one place.

100's of premium titles. One news app.

Start reading

UNCOVERED: Biib | History Defined

How Is Biogen’s Stock Performance Compared to Other Biotech Stocks?

Biogen has recently outperformed its industry peers, and analysts remain reasonably upbeat about the stock’s prospects.

Barchart

Biogen Stock Slides After Trial Miss, But Analysts Stay Bullish

Biogen’s Alzheimer’s drug candidate showed promising tau-targeting results despite missing a primary endpoint, reinforcing long-term optimism for BIIB stock

MarketBeat

Are Wall Street Analysts Bullish on Biogen Stock?

Biogen has rallied the broader market over the past year, and analysts remain moderately optimistic about the stock’s prospects.

Barchart

From analysis to the latest developments in health,
read the most diverse news in one place.

Biogen Conference: Lupus, Kidney Programs Take Center Stage in Immunology Push

Biogen (NASDAQ:BIIB) is continuing to position immunology as a larger part of its strategy, with late-stage lupus and kidney disease programs expected to shape the company’s next phase of growth, Adam Meyers, head of the company’s immunology and new disease areas franchise, said at Bank of America’s

MarketBeat

Biogen Earnings Preview: What to Expect

Biogen is poised to announce its first-quarter results next week, and analysts predict a marginal drop in the company’s bottom-line figure.

Barchart

Apellis Pharma Skyrockets on Biogen Deal. Is It Too Late to Chase APLS Stock?

Apellis Pharma stock more than doubled as Biogen announced a $5.6 billion acquisition. But for investors looking to jump into APLS shares now, the ship has already sailed.

Barchart

Biogen Stock: Is BIIB Outperforming the Healthcare Sector?

Biogen has outperformed its sector peers recently, and analysts remain moderately optimistic about the stock’s prospects.

Barchart

Read news from The Economist, FT, and more,
with one subscription

What Are Wall Street Analysts' Target Price for Biogen Stock?

Analysts are maintaining a generally positive outlook on Biogen's shares, noting recent stock strength and solid operational results.

Barchart

3 Biotech Stocks That Look Like “Sure-Fire” Winners in 2026

These three biotech stocks combine scale, late-stage pipelines, and analyst confidence, giving investors compelling upside potential in 2026

MarketBeat

What to Expect From Biogen's Next Quarterly Earnings Report

Biogen is expected to announce its fiscal fourth-quarter earnings soon, and analysts project a double-digit earnings drop.

Barchart

Is Biogen Stock Outperforming the Dow?

Biogen has notably outpaced the Dow in recent months and over the past year, and analysts remain moderately bullish on the stock’s prospects.

Barchart

Why Is Biogen Stock Trading Higher After Semaglutide Alzheimer's Data?

Biogen Inc. (NASDAQ:BIIB) stock traded higher after Novo Nordisk A/S (NYSE:NVO) released disappointing topline results from the 2-year primary analysis of Evoke and Evoke+ phase 3 trials in early-stage symptomatic Alzheimer's disease.

Benzinga

Biogen Stock: Is Wall Street Bullish or Bearish?

Despite Biogen's underperformance relative to the broader market over the past year, Wall Street analysts maintain a moderately optimistic outlook on the stock’s prospects.

Barchart

Biogen's Immunology Pipeline Has Long-Term Potential: Analyst

On Friday, Biogen Inc. (NASDAQ:BIIB) and Vanqua Bio announced a license agreement granting Biogen exclusive worldwide rights to Vanqua's preclinical, oral C5aR1 antagonist. The agreement strengthens Biogen's immunology.

Benzinga

Get all your
news in one place.

100's of premium titles.
One news app.

Barchart

What to Expect From Biogen’s Q3 2025 Earnings Report

Biogen is slated to release its fiscal third-quarter earnings later this month, and analysts are expecting its earnings to drop in the single-digit range.

Benzinga

Biogen Faces FDA Setback On High-Dose Nusinersen Filing For Spinal Muscular Atrophy

On Tuesday, the U.S. Food and Drug Administration (FDA) issued a Complete Response Letter (CRL) for Biogen Inc.’s (NASDAQ: BIIB) supplemental New Drug Application (sNDA) for the high-dose regimen of nusinersen for the treatment of spinal muscular atrophy (SMA).

Benzinga

Biogen's $85 Million Deal Could Change How Patients Get Spinraza Treatment

Biogen Inc. (NASDAQ:BIIB) on Thursday agreed to acquire Massachusetts-based Alcyone Therapeutics for $85 million.

Barchart

Is Biogen Stock Underperforming the Nasdaq?

Although Biogen has lagged behind the broader Nasdaq Composite over the past year, Wall Street analysts remain moderately optimistic about the stock’s prospects.

Get all your
news in one place.

100's of premium titles.
One news app.

Barchart

Biogen Stock: Analyst Estimates & Ratings

Biogen has lagged the broader market over the past year, yet analysts maintain a cautiously optimistic outlook on the stock’s future performance.

Benzinga

How Novo Nordisk's Weight-Loss Drug Could Unlock A Better Future For Biogen's Alzheimer's Treatment

Biogen Inc. (NASDAQ:BIIB) CEO Chris Viehbacher said a successful Alzheimer’s trial for Novo Nordisk A/S’ (NYSE:NVO) weight-loss drug wouldn’t threaten his company’s treatment but could instead open the door to combining therapies for stronger results.

Benzinga

Biogen Lifts Outlook As Rare Disease And Alzheimer's Drug Sales Accelerate

Biogen Inc. (NASDAQ:BIIB) reported on Thursday that the second quarter of 2025 adjusted earnings per share were $5.47, up 4% year over year, beating the analyst consensus of $4.06.

Benzinga

Biogen Bets Big On $2 Billion Expansion To Boost US Drug Manufacturing

Biogen Inc. (NASDAQ:BIIB) said on Monday that it plans to invest an additional $2 billion in its existing manufacturing footprint in North Carolina’s Research Triangle Park (RTP).

Barchart

Here's What to Expect From Biogen's Next Earnings Report

Biogen is expected to release its fiscal second-quarter earnings later this month, and analysts project a double-digit profit decline.

Barchart

Is Biogen Stock Underperforming the S&P 500?

Biogen has significantly underperformed the S&P 500 over the past year, but analysts are moderately optimistic about the stock’s prospects.

Barchart

Do Wall Street Analysts Like Biogen Stock?

Biogen has significantly underperformed the broader market over the past year, but analysts are moderately optimistic about the stock’s prospects.

1 2 3 4 5

People

Adam Meyers

22 stories

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.